Proteina Accelerates Global Push for New Osteoarthritis Drug 'PRT-101'

“Proving ‘Best-in-Class’ at EULAR”

Proteina, an AI-driven drug development company specializing in protein-protein interaction (PPI) big data, is aiming to establish its self-developed osteoarthritis treatment, PRT-101, as a 'Best-in-Class' therapy on the global stage.

According to Proteina on May 11, the company will participate in the 'European Congress of Rheumatology (EULAR 2026 Congress)' to be held in London, UK, from June 3 to 6, where it will release additional research findings. Notably, this year’s congress has selected Proteina’s research for the 'Poster Tour' session, which garners more attention than regular poster presentations, raising expectations for significant interest from global experts.

PRT-101 is an innovative first-in-class drug candidate that directly targets the SOX9 protein, a key transcription factor in cartilage formation, to promote its aggregation and thereby increase its activity. While existing approaches have focused on inhibiting abnormal aggregates or the activity of transcription factors, PRT-101 takes the opposite approach by precisely inducing the formation of SOX9 aggregates, which activates cartilage-forming genes and thereby achieves both structural regeneration of damaged cartilage and pain relief.

Currently, there are no drugs approved as disease-modifying osteoarthritis drugs (DMOADs) in the global osteoarthritis market. Lorecivivint, the leading candidate from US-based Biosplice, which has recently applied for new drug approval with the US FDA based on clinical results, serves as the benchmark for global osteoarthritis pipelines. At this congress, Proteina plans to present data showing that PRT-101 demonstrated superior cartilage regeneration and pain relief compared to leading competitor drugs in severe animal models, thereby further establishing its 'Best-in-Class' credentials. The company expects this data will serve as a key foundation for securing global partnerships. In addition, Proteina plans to hold follow-up meetings with multiple overseas partners with whom it engaged in discussions at the International Osteoarthritis Research Society (OARSI) in April, where the topic attracted significant interest.

Proteina is also conducting toxicity studies in rodents and non-rodents through a contract research organization (CRO) and is accelerating its commercialization timeline. The non-rodent toxicity study is a core regulatory requirement for submitting an Investigational New Drug (IND) application, and its completion effectively marks the final preclinical step before entering human clinical trials. Proteina intends to expedite the commercialization of PRT-101 by simultaneously advancing academic presentations, global partnering activities, and regulatory processes.

This content was produced with the assistance of AI translation services.